FinnGen
Overview
FinnGen is a Finnish public-private genomics research consortium coordinated by the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, partnering nine Finnish biobanks, major Finnish university hospitals, and thirteen international pharmaceutical companies. GWAS summary statistics for over 2,400 disease endpoints, derived from a cohort of more than 500,000 genotyped participants, are released publicly after a twelve-month embargo and are freely downloadable from Google Cloud Storage. The Finnish population’s genetic distinctiveness, due to historical demographic isolation, makes FinnGen well powered for identifying rare variants and fine-mapping disease loci. Neurological and psychiatric endpoints are extensively covered, and FinnGen summary statistics feed into the Open Targets Platform and ENIGMA Consortium meta-analyses.
Notable datasets
FinnGen GWAS summary statistics are released publicly after a twelve-month embargo from each data freeze. Data Freeze 12 (2024) covers 500,000+ participants and 2,400+ disease endpoints and is freely downloadable from Google Cloud Storage. Individual-level genotype and phenotype data are controlled-access via Finnish biobanks through the Fingenious portal, with a subset deposited to EGA.
Connections
- registeredIn: EGA (individual-level controlled-access genomic and phenotypic data)
- relatedTo: BBMRI-ERIC (Finnish biobanks participating in FinnGen are BBMRI-ERIC national nodes via FINBB)
- relatedTo: ENIGMA Consortium (FinnGen summary statistics used in ENIGMA neuroimaging-genetics meta-analyses)
Resources
- https://www.finngen.fi
- https://r12.finngen.fi (FinnGen Data Freeze 12 summary statistics)
- https://doi.org/10.1038/s41586-023-06433-6